141790-23-0

141790-23-0 structure

Name: Fozivudine tidoxil
Chemical Name: [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
CAS Number: 141790-23-0
Molecular Formula: C₃₅H₆₄N₅O₈PS
Molecular Weight: 745.95000
Catalog: Signaling Pathways Anti-infection HIV
Create Date: 2018-05-09 08:00:00
Modify Date: 2024-01-20 11:42:28
Fozivudine tidoxil (BM-211290) is an orally active thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity. Fozivudine tidoxil, a member of the NRTI family of drug, is incorporated into the newly synthesized strand of DNA during intracellular viral replication and irreversibly binds viral RT which disrupts viral reverse-transcription[1][2].

Name	[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
Synonyms	fozivudine tidoxil fosphenyloin Fosfenitoina Fosphenytoinum 3-Phosphoryloxymethyl-diphenylhydantoin HMPDP Fosphenytoine oxcarbamazepine Prodilantin Fosphenytoin 3-phosphoryloxymethyl-5,5-diphenylhydantoin

Description	Fozivudine tidoxil (BM-211290) is an orally active thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity. Fozivudine tidoxil, a member of the NRTI family of drug, is incorporated into the newly synthesized strand of DNA during intracellular viral replication and irreversibly binds viral RT which disrupts viral reverse-transcription[1][2].
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection Signaling Pathways >> Cell Cycle/DNA Damage >> DNA/RNA Synthesis
Target	HIV
In Vitro	Fozivudine tidoxil (BM-211290) is a member of the nucleoside analogue reverse transcriptase inhibitor (NRTI) family[1].
In Vivo	Fozivudine tidoxil (BM-211290; 45 mg/kg; PO; twice daily; one day before FIV challenge for a total of six weeks) is effective at lowering plasma- and cell-associated viremia at two weeks post-FIV infection[1]. Animal Model: Specific pathogen-free cats at 6 months of age[1] Dosage: 45 mg/kg Administration: PO; twice daily; one day before FIV challenge for a total of six weeks Result: Effective at lowering plasma- and cell-associated viremia at two weeks post-feline immunodeficiency virus (FIV) infection with a trend toward lower plasma- and cell- associated viremia at four and six weeks post-infection (PI).
References	[1]. Michelle M Miller, et al. Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic During Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection. Viruses. 2012 Jun;4(6):954-62. [2]. P M Girard, et al. Phase II Placebo-Controlled Trial of Fozivudine Tidoxil for HIV Infection: Pharmacokinetics, Tolerability, and Efficacy. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):227-35.

Molecular Formula	C₃₅H₆₄N₅O₈PS
Molecular Weight	745.95000
Exact Mass	745.42100
PSA	214.20000
LogP	8.99006

141790-23-0	763903-67-9
174638-15-4	1158522-08-7
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1
127437-46-1